Dulaglutide Injection

DRUG7 trials

Sponsors

Emory University, Vanderbilt University Medical Center, Sunshine Lake Pharma Co., Ltd., Fujian Shengdi Pharmaceutical Co., Ltd., The Affiliated Hospital of Xuzhou Medical University

Conditions

Bipolar DisorderChronic Kidney DiseasesCognitionDiabetes Mellitus, Type 2ObesityStress HyperglycemiaType 2 DiabetesType 2 Diabetic Nephropathy

Phase 1

A Pharmacokinetic Study Comparing the 14028 Injection and TRULICITY® in Healthy Chinese Subjects

CompletedNCT05459285

Sunshine Lake Pharma Co., Ltd.Type 2 Diabetes

Start: 2022-05-31End: 2022-07-08Updated: 2022-08-25

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Subcutaneous Injections of HRS9531 in Patients With Type 2 Diabetes Mellitus

CompletedNCT05516966

Fujian Shengdi Pharmaceutical Co., Ltd.Diabetes Mellitus, Type 2

Start: 2022-10-12End: 2023-05-24Updated: 2024-11-15

Phase 2

Effects of GLP1-RA on Ectopic Fat Deposition in Chronic Kidney Disease

CompletedNCT05254418

Vanderbilt University Medical CenterChronic Kidney Diseases

Start: 2022-03-15End: 2024-08-01Updated: 2025-04-20

Phase 3

A Phase 3 Study of HS-20094 in Patients With T2DM

Not yet recruitingNCT07156539

Jiangsu Hansoh Pharmaceutical Co., Ltd.Type 2 Diabetes

Start: 2025-09-30End: 2027-05-30Target: 546Updated: 2025-09-05

Phase 4

Metabolic Phenotyping During Stress Hyperglycemia in Cardiac Surgery Patients

TerminatedNCT03743025

Emory UniversityStress Hyperglycemia

Start: 2019-03-08End: 2023-05-02Updated: 2024-05-30

Unknown Phase

Renoprotective Effects of Dulaglutide in Patients With Type 2 Diabetic Nephropathy

CompletedNCT06182891

The Affiliated Hospital of Xuzhou Medical UniversityType 2 Diabetic Nephropathy

Start: 2021-10-30End: 2023-10-30Updated: 2023-12-27

The Effect of Dulaglutide as an Adjuvant Therapy on Cognitive Function in Bipolar Disorder Patients With Obesity

First Affiliated Hospital of Zhejiang UniversityBipolar Disorder, Cognition, Obesity

Start: 2023-09-01End: 2024-12-31Target: 60Updated: 2024-03-26